Sol-Gel Technologies Ltd. (SLGL) has a MoatMap StockRank of 46/100 based on Quality (38/100), Value (32/100), and Momentum (62/100) factor scores. The current signal is HOLD. Sol-Gel Technologies Ltd. is an Israeli pharmaceutical company. Its focus on dermatology products, without a clear connection to the fund's macro themes for asymmetric opportunity, and insufficient information on its quality compounder attributes (e.g., ROIC, moat strength), makes it unsuitable for a high-conviction investment.
Sol-Gel Technologies Ltd. is a specialty pharmaceutical company focused on developing and commercializing dermatology products by leveraging its proprietary microencapsulation technology, with a pipeline addressing conditions like acne and rosacea. Its competitive moat is built upon the Sol-Gel platform, which enhances drug delivery, stability, and reduces side effects, differentiating its topical treatments. The company benefits from strong intellectual property and a focused approach within the large and growing dermatology market.
| Price | $76.73 |
| Market Cap | $249M |
| P/E (Forward) | -4.30 |
| Price/Book | 7.73 |
| Return on Equity | -23.7% |
| Return on Invested Capital | -31.7% |
| Debt/Equity | 4.34 |
| Gross Margin | -17.6% |
| Operating Margin | -497.8% |
| Revenue Growth | 150.4% |
| Free Cash Flow | $617K |
Sol-Gel Technologies Ltd. operates in the Biotechnology industry, part of the Healthcare sector (Israel).